CN110446490B - 包含米拉贝隆或其盐的用于调节释放的药剂学组合物 - Google Patents

包含米拉贝隆或其盐的用于调节释放的药剂学组合物 Download PDF

Info

Publication number
CN110446490B
CN110446490B CN201880018616.8A CN201880018616A CN110446490B CN 110446490 B CN110446490 B CN 110446490B CN 201880018616 A CN201880018616 A CN 201880018616A CN 110446490 B CN110446490 B CN 110446490B
Authority
CN
China
Prior art keywords
modified release
pharmaceutical composition
mirabegron
polyethylene oxide
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880018616.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110446490A (zh
Inventor
金秀妍
金暋洙
徐惠珍
朴信政
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of CN110446490A publication Critical patent/CN110446490A/zh
Application granted granted Critical
Publication of CN110446490B publication Critical patent/CN110446490B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CN201880018616.8A 2017-03-17 2018-03-15 包含米拉贝隆或其盐的用于调节释放的药剂学组合物 Expired - Fee Related CN110446490B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0033944 2017-03-17
KR1020170033944A KR102051132B1 (ko) 2017-03-17 2017-03-17 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
PCT/KR2018/003043 WO2018169325A1 (ko) 2017-03-17 2018-03-15 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물

Publications (2)

Publication Number Publication Date
CN110446490A CN110446490A (zh) 2019-11-12
CN110446490B true CN110446490B (zh) 2023-04-04

Family

ID=63522330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018616.8A Expired - Fee Related CN110446490B (zh) 2017-03-17 2018-03-15 包含米拉贝隆或其盐的用于调节释放的药剂学组合物

Country Status (4)

Country Link
JP (2) JP2020510679A (https=)
KR (1) KR102051132B1 (https=)
CN (1) CN110446490B (https=)
WO (1) WO2018169325A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021069944A1 (en) * 2019-10-09 2021-04-15 Alvogen Korea Co., Ltd. Pharmaceutical composition comprising mirabegron and process for manufacturing the same
KR102546923B1 (ko) 2020-03-03 2023-06-26 동광제약 주식회사 미라베그론을 포함하는 제어 방출 제제
WO2023022520A1 (ko) * 2021-08-18 2023-02-23 주식회사 삼양홀딩스 룩소리티닙의 경구용 정제 조성물 및 이의 제조 방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
WO2024144207A1 (en) * 2022-12-26 2024-07-04 Rexpharmtech Co., Ltd Sustained-release tablet comprising apixaban
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
TR2024008630A1 (tr) 2024-07-04 2026-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇rabegron i̇çeren modi̇fi̇ye salimli bi̇r tablet bi̇leşi̇mi̇

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501022A (ja) * 1998-01-22 2002-01-15 アボット・ラボラトリーズ 副作用の少ない持続放出性チアガビン製剤
CN105232448A (zh) * 2008-09-30 2016-01-13 安斯泰来制药株式会社 控释药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3815496B2 (ja) * 2002-11-07 2006-08-30 アステラス製薬株式会社 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤
JP2007516297A (ja) * 2003-12-23 2007-06-21 アルザ・コーポレーシヨン 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
EP2832730A4 (en) * 2012-03-30 2015-09-09 Astellas Pharma Inc MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
EA201590449A1 (ru) * 2012-08-31 2015-06-30 Астеллас Фарма Инк. Перорально вводимая лекарственная композиция
CN104288116A (zh) * 2014-09-05 2015-01-21 南京华威医药科技开发有限公司 一种米拉贝隆缓释片组合物
KR20170088783A (ko) * 2017-07-07 2017-08-02 지엘팜텍주식회사 미라베그론의 습식과립 조성물
EP3292864A1 (en) * 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501022A (ja) * 1998-01-22 2002-01-15 アボット・ラボラトリーズ 副作用の少ない持続放出性チアガビン製剤
CN105232448A (zh) * 2008-09-30 2016-01-13 安斯泰来制药株式会社 控释药物组合物

Also Published As

Publication number Publication date
KR20180106185A (ko) 2018-10-01
JP2020510679A (ja) 2020-04-09
JP2021185139A (ja) 2021-12-09
KR102051132B1 (ko) 2019-12-02
WO2018169325A1 (ko) 2018-09-20
CN110446490A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
CN110446490B (zh) 包含米拉贝隆或其盐的用于调节释放的药剂学组合物
JP7627302B2 (ja) パルボシクリブの固形剤形
KR20230093401A (ko) 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
CN108697803A (zh) 透粘膜给药的药物组合物
EP2200591A2 (en) Controlled release pharmaceutical dosage forms of trimetazidine
EA021784B1 (ru) Фармацевтические композиции с длительным высвобождением
JP6768070B2 (ja) 粘膜付着性医薬組成物及びその製造方法
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
JP2021185139A5 (https=)
JP2016510065A (ja) 有機化合物の製剤
JP5713421B1 (ja) 口腔内崩壊錠
CN108174596A (zh) 包含8-[(3r)-3-氨基-1-哌啶基]-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[4-甲基-2-喹唑啉基)甲基]-1h-嘌呤-2,6-二酮或其药学上可接受的盐的药物组合物
US20060240101A1 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2015152680A1 (en) Granule comprising silodosin, and pharmaceutical composition and formulation comprising same
EP3697392B1 (en) Tablets comprising tamsulosin and solifenacin
Al Hablawi et al. Formulation Variables Influencing the Development of Ketoconazole Gastroretentive Drug Delivery System
EP2744484A1 (en) Pharmaceutical composition comprising 4-[4[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
JP2024067030A (ja) ミラベグロン含有放出制御医薬組成物及びその製造方法
Bühler et al. Generic drug formulations
JP2023071921A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
Devi et al. Formulation and evaluation of gastroretentive floating tablets of diclofenac sodium based on effervescent technology
HUP0600237A2 (en) Pharmaceutical tablet comprising paroxetine mesylate
EP4725474A1 (en) A solid composition of eliglustat
Almotairy Formulation Development and Targeted Delivery for BCS II Drugs Using Hot Melt Extrusion Technology
HUP0101739A2 (hu) Nyújtott hatású tiagabin készítmények csökkentett mellékhatásokkal

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230404